AIDSInfo logo
Home > Clinical Guidelines > Pediatric Guidelines

Pediatric Guidelines

Related Content

Order PublicationSupplementsSlide SetsManualsFact Sheets
DrugsHow to CiteClinical Trials 
Adapted from Pediatric Treatment Guidelines Table 7: Recommended Antiretroviral Regimens for Initial Regimens for Initial Therapy for HIV Infection in Children (Updated July 29, 2008)

NNRTI-Based Regimens


  Children 3 years or older:
  Children younger than 3 years (or who can't swallow capsules):

2 NRTIs* plus efavirenz

2 NRTIs* plus nevirapine

Alternate (children 3 years or older): 2 NRTIs* plus nevirapine
PI-Based Regimens
Preferred: 2 NRTIs* plus lopinavir/ritonavir
Alternate (listed alphabetically):




2 NRTIs* plus atazanavir plus low dose ritonavir (children 6 years or older)

2 NRTIs* plus fosamprenavir plus low dose ritonavir (children 6 years or older)

2 NRTIs* plus nelfinavir (children 2 years or older)


Use in Special Circumstances






* NRTI Backbone Options (For use in combination with additional drugs) (alphabetical order)

2 NRTIs* plus atazanavir unboosted (for treatment-naive adolescents 13 years or older and >39 kg)

2 NRTIs* plus fosamprenavir unboosted (children 2 years or older)

2 NRTIs* plus saquinavir plus low dose ritonavir only in post-pubertal adolescents who weigh enough to receive adult doses

Zidovudine plus lamivudine plus abacavir


Abacavir plus (lamivudine or emtricitabine)

Didanosine plus emtricitabine 

Tenofovir plus (lamivudine or emtricitabine) (for Tanner Stage 4 or post-pubertal adolescents only) 

Zidovudine plus (lamivudine or emtricitabine


Abacavir plus zidovudine


Use in Special Circumstances:

Zidovudine plus didanosine

Stavudine plus (lamivudine or emtricitabine)

How to Cite the Pediatric Guidelines:
Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. July 29, 2008; pp 1-134. Available at Accessed (insert date) [include page numbers, table number, etc. if applicable]
Clinical TrialsBack
3 studies were listed in the last 30 days.            

Not yet recruitingSafety And Efficacy Of Rifabutin In HIV Patients.
Condition: Non-Tuberculous Mycobacterial Diseases (Including MAC Disease); Tuberculosis; Inhibition of Disseminated Mycobacterium Avium Complex (MAC) Disease Associated With HIV Infections; HIV Infections
Not yet recruitingEvaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy.
Condition: HIV; Malaria; HIV Infections
RecruitingLopinavir/Ritonavir (Kaletra)PK
Condition: HIV/AIDS Treatment; HIV Infections
Important Notice:
This document has been submitted for publication to CDC's Morbidity and Mortality Weekly Report (MMWR) and should be considered a final draft. It is being posted on AIDSinfo to expedite dissemination of important clinical information. Upon acceptance and publication in MMWR, this draft will be removed and replaced by the published version. In the meantime, readers should be aware that the content of the draft might differ from the content of future published versions. Any corrections/questions concerning this document should be addressed to Ms. Jessica Carrington (e-mail:
Close window